Floatz logo

2-PROPEN-1-ONE, 1-(2-FLUOROPHENYL)-3-(4-HYDROXYPHENYL)-, O-(2-(DIMETHYLAMINO)ETHYL)OXIME, (1Z,2E)-

Fibromyalgia

SanofiSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
89/ 100

Competitive context

13 Active assets in the Fibromyalgia cohort.

Asset / SponsorPhaseRating
Duloxetine
Cukurova University
Phase 4BBB
Pregabalin
Yung Shin Pharm. Ind. Co., Ltd.
Phase 4BB
PIPERAZINE, 1-(BIS(4-FLUOROPHENYL)METHYL)-4-(3-PHENYL-2-PROPENYL)-, (E)-
Taipei Veterans General Hospital, Taiwan
Phase 4BB
LIDOCAINE
Peking University Third Hospital
Phase 2BB
CYCLOHEXANEACETIC ACID, 1-(AMINOMETHYL)-
Good Samaritan Regional Medical Center, Oregon
Phase 3B

View all 36 →

Same molecule, other indications

2-PROPEN-1-ONE, 1-(2-FLUOROPHENYL)-3-(4-HYDROXYPHENYL)-, O-(2-(DIMETHYLAMINO)ETHYL)OXIME, (1Z,2E)- is also rated in:

sleep disorderDormant
B
Indicative ·
57 / 100
View asset →
chronic pain syndromeDormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →